EARLY STAGE TRIPLE-NEGATIVE BREAST CARCINOMA
Clinical trials for EARLY STAGE TRIPLE-NEGATIVE BREAST CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new EARLY STAGE TRIPLE-NEGATIVE BREAST CARCINOMA trials appear
Sign up with your email to follow new studies for EARLY STAGE TRIPLE-NEGATIVE BREAST CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Custom-Made vaccine takes on tough breast cancer
⭐️ VACCINE ⭐️ Recruiting nowThis early-stage trial tests a personalized vaccine made from a patient's own tumor, given alone or with drugs that boost the immune system (pembrolizumab or ipilimumab). The goal is to see if the vaccine is safe and can help the immune system fight triple negative breast cancer …
Matched conditions: EARLY STAGE TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE1 • Sponsor: Emory University • Aim: ⭐️ VACCINE ⭐️
Last updated May 11, 2026 20:37 UTC
-
Could a shorter chemo regimen spare thousands from harsh side effects?
Disease control Recruiting nowThis study compares a shorter chemotherapy-immunotherapy regimen without anthracyclines to the standard longer treatment for people with early-stage triple negative breast cancer. About 2,400 participants will receive either the experimental shorter treatment or the usual care. T…
Matched conditions: EARLY STAGE TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE3 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated May 15, 2026 12:07 UTC
-
New drug combo shows promise in early aggressive breast cancer trial
Disease control Recruiting nowThis study tests whether adding the drug ivonescimab to standard chemotherapy before surgery can improve outcomes for people with early-stage triple-negative breast cancer. About 34 participants will receive the combination every three weeks for six cycles, then undergo surgery. …
Matched conditions: EARLY STAGE TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: Cedars-Sinai Medical Center • Aim: Disease control
Last updated May 11, 2026 20:49 UTC
-
BREAST CANCER BREAKTHROUGH: could less treatment be just as effective?
Disease control Recruiting nowThis study is for people with early-stage triple-negative breast cancer who had a complete response (no cancer left) after chemotherapy plus the immunotherapy drug pembrolizumab. The trial compares receiving more pembrolizumab versus simply being watched (observation) to see if t…
Matched conditions: EARLY STAGE TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated May 04, 2026 16:22 UTC
-
Tumor tissue study aims to predict cancer treatment success
Knowledge-focused Recruiting nowThis study collects tissue samples from people with various advanced or early-stage cancers to train a new diagnostic platform called Elephas. The goal is to see how accurately it can predict whether a patient will respond to immunotherapy or chemoimmunotherapy. About 324 partici…
Matched conditions: EARLY STAGE TRIPLE-NEGATIVE BREAST CARCINOMA
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated May 15, 2026 11:54 UTC